Table 3. Peptide-Based Inhibitors of HCV Entry, Their Sequences, and the Available Inhibition Data.

target	name	sequence	efficiency of inhibition
CD81	710–725178	ASWAIKWEYVVLLFLL	∼60% relative luciferase activity at 51 μMa
	CD81-binding nonapeptide182	SPQYWTGA motif	NA
	CL58179	MANAGLQLLGFILAFLGW	IC50 = 2.1 ± 0.5 μM
E2	hCD81-like nonapeptide184	ATWVCGPCT	E2 inhibits binding of C9 clone to anti-hCD81 JS-81 with inhibition ratio of 67.5%
	SAHH-5181	PSGSNXSNIISNXFRED	EC50 = 17–39 μMb
	C18183	WPWHNHR	Relative level of HCV RNA ∼ 0.5 at 97 μMc
	E2–42180	QGSWFGCTWMNSTGF	% of infectivity at C = 5 nM: 50–60%

^aLuciferase activity in Huh7.5 cells compared to the activity in PBS buffer.

^bValue depending on the HCV subtype.

^cIn Huh7.5 cells infected with HCVcc.